SELF STUDY / ENDURING – ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes

Overview

Multiple myeloma (MM) is a currently incurable malignancy that is primarily characterized by immunodeficiency, malignant plasma cell proliferation, and osteolytic bone lesions. MM is the 2nd second most common hematologic malignancy worldwide, with approximately ~35,000 new cases and more than 12,000 deaths annually in the United States, Despite advancements in first-line therapies and improved overall survival (OS) rates, most patients will experience a relapse and require additional treatments. This seminar will address health inequities and highlight the challenges and best practices associated with successful community-based approaches to patient care.

Learning Objectives

1. Describe the mechanism-of-action of new and emerging therapies for the treatment of relapsed remitting multiple myeloma (RRMM)
2. Review clinical evidence on the utility and potential sequencing of new and emerging RRMM treatment approaches with or without planned transplant
3. Evaluate disparities in RRMM care and overall survival rates relative to treatment setting and ethnicity, particularly black patients
4. Leverage RRMM treatment advances to overcome treatment disparities and optimize patient outcomes